GlassScriptPhysician profile
Padma Venkataraman
NPI 1881925204
$802.68
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.57 · 2022: $457 · 2023: $300 · 2024: $13.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $220.33 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $167.29 | 2022-2023 | Lokelma |
| Sanofi-Aventis U.S. LLC | $47.44 | 2022-2023 | |
| Dexcom, INC. | $45.51 | 2022-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $43.20 | 2022-2023 | Synthroid |
| Corcept Therapeutics | $41.80 | 2022-2023 | Korlym |
| Lilly USA, LLC | $40.07 | 2022 | |
| Vifor Pharma, INC. | $34.86 | 2022 | |
| Insulet Corporation | $33.90 | 2023-2024 | Omnipod |
| Pfizer INC. | $27.54 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $21.16 | 2022 | |
| Glaxosmithkline, LLC. | $19.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.48 | 2023 | |
| Depuy Synthes Sales INC. | $15.67 | 2022 | |
| Ibsa Pharma INC. | $13.86 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Venkataraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.